Structure-based design of targeted covalent inhibitors
Author:
Affiliation:
1. Chemistry
2. Oncology
3. IMED Biotech Unit
4. AstraZeneca
5. Cambridge
Abstract
Covalent inhibition is a rapidly growing discipline within drug discovery.
Funder
AstraZeneca
Publisher
Royal Society of Chemistry (RSC)
Subject
General Chemistry
Link
http://pubs.rsc.org/en/content/articlepdf/2018/CS/C7CS00220C
Reference50 articles.
1. The art and practice of structure-based drug design: A molecular modeling perspective
2. The resurgence of covalent drugs
3. Targeting cancer with small molecule kinase inhibitors
4. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
5. Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Cited by 227 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Discovery and development of quinazoline compounds as irreversible pan-fibroblast growth factor receptor inhibitors with potent antitumor activities;Journal of Molecular Structure;2024-03
2. Peptide-Based Covalent Inhibitors Bearing Mild Electrophiles to Target a Conserved His Residue of the Bacterial Sliding Clamp;JACS Au;2024-01-25
3. Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres;International Journal of Molecular Sciences;2024-01-23
4. Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches;Journal of Personalized Medicine;2024-01-04
5. Covalent hits and where to find them;SLAS Discovery;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3